Imlunestrant is a next generation, brain penetrant, oral selective estrogen receptor degrader that delivers continuous ER inhibition even in cancers with mutations in the gene encoding ESR 1.
Among patients with ER positive, HER2 negative advanced breast cancer Imlunestrant led to significantly longer progression free survival than standard therapy among those with ESR one mutations but not in the overall population.
The combination of Imlunestrant and abemaciclib significantly improved progression free survival as compared with Imlunestrant, regardless of the ESR 1 mutation status.